2Department of Nursing, Eskişehir Osmangazi University Faculty of Health Science, Eskişehir-Türkiye DOI : 10.5505/tjo.2024.4202
Summary
OBJECTIVEThis study was conducted to evaluate the supportive care needs and coping attitudes of breast cancer patients according to their neuropathic pain status.
METHODS
This case-control study design was conducted with 212 patients who were being treated in the daily
chemotherapy unit of a hospital in İstanbul, who agreed to participate in the study and met the inclusion
criteria. The S-LANSS pain scale was used to determine the neuropathic pain status of the patients. A
Descriptive Information Form, Supportive Care Needs Scale, and Coping Attitudes Scale were used to
collect the data.
RESULTS
The study sample consisted of case group patients with neuropathic pain (n=100) and control group
patients without neuropathic pain (n=112). The mean age of the participants was 50 (45-54) in the case
group and 49 (45-57) in the control group. In the case group, 24.5% used paclitaxel chemotherapy, and
40.6% had no knowledge about neuropathic pain. In the control group, 21.7% used paclitaxel chemotherapy,
and 46.2% had no knowledge about neuropathic pain. There was no statistically significant
difference between the groups in terms of total scores and sub-dimensions of the Supportive Care Needs
Scale and total scores and sub-dimensions of the Coping Orientations to Problems Experienced scale.
CONCLUSION
Coping attitudes and supportive care needs of patients do not change according to the presence of neuropathic
pain. Nearly half of the patients receiving neurotoxic chemotherapy, which frequently causes
neuropathic pain, have no knowledge about neuropathic pain.
Introduction
Breast cancer is the most common cancer in women worldwide and in Türkiye, its incidence is increasing, and it is life-threatening.[1] Chemotherapy, commonly used in the treatment of breast cancer, has many side effects in addition to its therapeutic effects.[2,3] Peripheral neuropathy is among the side effects observed especially due to neurotoxic chemotherapy.[4]Chemotherapy-associated peripheral neuropathy or chemotherapy-induced peripheral neuropathy (CIPN) is a frequently encountered symptom in individuals treated with taxane and platinum compounds, vinca alkaloids, antiangiogenesis agents, and proteasome inhibitors.[5,6] This negatively affects the quality of life of patients.[4] In a randomized controlled study, it was reported that individuals frequently experienced pain, sensitivity to cold, burning sensations, numbness, and tingling as symptoms of CIPN.[7] Symptoms due to CIPN prevent the fulfillment of needs in many areas of life, including the most basic activities of daily living such as dressing, showering, eating, and walking.[8]
According to the literature, it has been reported that cancer patients" supportive care needs in psychological and physical areas are not met.[9,10] Cancer patients face both physical and psychological symptoms and undergo a challenging process. In this process, patients should be able to develop effective coping methods to overcome negative situations.[11] When studies on cancer patients are examined, it is seen that patients mostly use religious coping attitudes.[12,13]
In the literature, there are studies on CPPN, quality of life, and coping methods,[14-17] but the effect of neuropathic pain on supportive care needs and coping attitudes has not been evaluated.
Methods
Aim and Type of ResearchThe aim of this study was to evaluate the supportive care needs and coping attitude levels of breast cancer patients according to their neuropathic pain status. The type of research is a comparative study in a case-control study design.
Hypotheses of the Study
H1: The supportive care needs of breast cancer patients
vary according to their neuropathic pain status.
H2: The coping attitude levels of breast cancer patients
vary according to their neuropathic pain status.
Population and Sample of the Study
The population of the study consisted of patients who
were being treated in the daily chemotherapy service of
a hospital in Istanbul between December 1, 2022, and
July 1, 2023. The sample of the study consisted of 212
patients who met the inclusion criteria from the study
population. Patients were divided into case (n=100)
and control (n=112) groups according to the presence
of neuropathic pain.
Inclusion Criteria
Case Group
• Receiving taxane group chemotherapy,
• Scores of 12 or more on the S-LANSS pain scale,
• At least one course of chemotherapy,
• Patients who are conscious and able to answer
questions.
Control Group
• Receiving taxane group chemotherapy,
• Score below 12 on the S-LANSS pain scale,
• At least one course of chemotherapy,
• Patients who are conscious and able to answer
questions.
Exclusion Criteria
• Patients under 18 years of age,
• Diagnosis of bone metastases and diabetes,
• Receiving any treatment other than taxane group
chemotherapy,
• Completion of taxane group chemotherapy.
Limitations of the Study
The results obtained from the study include voluntary
patients who received chemotherapy at a specified institution
in Istanbul and within a certain time interval
and met the inclusion criteria. These results cannot be
generalized to all patients receiving chemotherapy.
Data Collection
Before starting the study, patients were informed about
the purpose and method of the study and asked whether
they were willing to participate. Written informed consent
was obtained from those who volunteered to participate.
The Descriptive Information Form, S-LANSS
(Self-Leeds Assessment of Neuropathic Symptoms and
Signs) Neuropathic Pain Scale, Supportive Care Needs
Scale Short Form (DeBGÖ-KFTr), and Coping Attitudes
Scale (COPE) were used to collect data.
The questionnaires were administered in a quiet room in the daytime chemotherapy unit using a faceto- face interview technique, with patients completing the forms in approximately 20 minutes. Patients with a score of 12 and above on the S-LANSS pain scale were assigned to the case group, and those with a score below 12 were assigned to the control group.
Descriptive Information Form
It includes questions about the patient's age, marital
status, education, employment status, income level,
presence and type of chronic disease, smoking and alcohol use, chemotherapy protocol, cycle, neuropathy
symptoms, information about CPPN, and perception
of social support.[18-20]
S-LANSS Pain Scale
It is used to distinguish between neuropathic and nociceptive
pain. It was developed by Bennett et al.[21]
by modifying the LANSS (Leeds Assessment of Neuropathic
Symptoms and Sign) Pain Scale. The validity
and reliability study of the scale was conducted by Rabia
Koç.[22] Questions on the scale are answered with
"yes" or "no," with possible scores ranging from 0 to 24.
A score of 12 or above indicates neuropathic pain. The
Cronbach's ? value of the pain scale was found to be
0.73 and 0.74.[22]
Supportive Care Needs Scale Short Form
(DeBGÖ-KFTr)
This scale, developed by Boyes et al.,[23] aims to
identify patients" supportive care needs. Özbayır et
al.,[19] who conducted the Turkish validity and reliability
of the scale, determined the number of items
as 29. DBGÖ-KF29 addresses four different aspects
of supportive care needs: health care and information
(14 items), daily living (5 items), sexuality (3
items), and psychological needs (7 items). Each item
is scored from 1 to 5 points, with the total score ranging
from 29 to 145 points. Higher scores indicate a
greater need for supportive care. The Cronbach's ?
value of the scale was found to be between 0.86 and
0.96 in the study by Boyes et al.[23] and 0.99 in the
study by Özbayır et al.[19]
COPE - The Coping Orientations to Problems
Experienced Scale
Developed by Carver and Scheier (1989), the COPE
inventory (The Coping Orientations to Problems Experienced
Scale) evaluates coping attitudes used when
faced with difficult events in daily life.[24] The Turkish
validity and reliability study was conducted by
Ağargün et al.[25] The scale consists of 60 questions
and 15 subscales, each with four questions providing
information about a separate coping attitude. Higher
scores from the subscales allow for an assessment of
which coping attitudes are more frequently used. The
15 sub-dimensions are:
1. Positive reinterpretation and growth,
2. Mental disengagement,
3. Focus on and venting of emotions,
4. Use of instrumental social support,
5. Active coping,
6. Denial,
7. Religious coping,
8. Humor,
9. Behavioral disengagement,
10. Restraint,
11. Use of emotional social support,
12. Substance use,
13. Acceptance,
14. Suppression of competing activities,
15. Planning.
The Cronbach's alpha value of the scale is 0.94.[25]
Statistical Analysis
Data from the study were analyzed using IBM SPSS
(Statistical Package for Social Science) Statistics
25.0. Summary statistics for quantitative variables
were presented as frequency and percentage. The
Kolmogorov-Smirnov test assessed data normality.
The independent samples t-test was used for group
comparisons with normal distribution, and the
Mann-Whitney U test was used for group comparisons
without normal distribution. The chi-square test
(chi-square test with Yates Correction, Pearson's exact
chi-square test) evaluated relationships between categorical
variables. Significance was set at p<0.05 in
the statistical evaluation.[26]
Ethical Dimension
Permission was obtained from the university's clinical
research ethics committee and subsequently from
the Istanbul Provincial Directorate of Health. The informed
consent form was explained to participating
individuals, and their permission was obtained. Patients
were informed that they could withdraw from
the study at any time without giving a reason.
Results
The mean age of the patients was 50 (45-54) in the case group and 49 (45?57) in the control group. In the case group, 40.1% were single or widowed, 22.2% were primary school graduates, and 37.3% had an income equivalent to expenditure. In the control group, 42% were single or widowed, 24.5% were primary school graduates, and 43.4% had equal income and expenditure status (Table 1). Both groups were homogeneous in terms of marital status, education, and income (p>0.05).;){kind=link}
Table 1 Distribution of socio-demographic characteristics of case-control group patients
Among the patients in the case group, 31.1% had no chronic disease, 24.5% used taxane group chemotherapy, and 40.6% were unaware of neuropathic pain; in the control group, 34.9% had no chronic disease, 21.7% used taxane group chemotherapy, and 46.2% were unaware of neuropathic pain (Table 2). There was no statistically significant difference between the groups regarding knowledge of chronic disease and neuropathic pain (p>0.05), whereas there was a statistically significant difference between the groups according to the chemotherapy protocol applied (p<0.05).
;){kind=link}
Table 2 Distribution of medical characteristics of case-control group patients
Table 3 presents the total scores of the patients" supportive care needs and coping attitudes and the scores of the sub-dimensions of the scales. According to this table, there is no statistically significant difference between the total and sub-dimension scores of the Supportive Care Needs Scale and the total and sub-dimension scores of the Coping Attitudes Scale between the groups (p>0.05). Examination of the mean scores of the total score and sub-dimensions of the groups reveals close values. This indicates that the levels of supportive care needs and coping attitudes of both the case and control groups are similar.
;){kind=link}
Table 3 DEBGÖ-KFTr and COPE score distributions of case-control group patients
Discussion
CIPN is one of the most common neurotoxicities in women with breast cancer treated with taxane and platinum-based chemotherapy. CIPN may lead to treatment dose reduction, treatment change, and treatment discontinuation.[27-30] In a systematic review, the incidence of CIPN was reported as 70-100% in platinum group treatments, while this rate was 11-87% in taxane group treatments.[31] Another study reported the incidence of peripheral neuropathy due to oxaliplatin, cisplatin, and carboplatin treatments in solid tumor therapy as 50-85%. [32] It was also reported that the frequency of acute COPD in oxaliplatin treatment was 90% and chronic COPD was 30-50%.[33] When cisplatin and paclitaxel were administered together, the incidence of CIPN was 69-76%. In the same study, the incidence of cisplatin-induced CIPN was 12-84% and paclitaxel- induced CIPN was 61-92%.[29] In our study, 24.5% of the case group and 21.7% of the control group received taxane group chemotherapy; 9% of the case group and 8% of the control group received combined taxane and platinum group chemotherapy. A significant difference was found according to the chemotherapy protocols applied (Table 2, p<0.05). Although there was a similarity with the literature in terms of the types of chemotherapy causing CIPN in the control group, chemotherapies causing CIPN were also used in the control group without neuropathic pain. This may be due to various risk factors such as chemotherapy administration rate, cumulative dose, gender, age, chronic disease, and genetic predisposition affecting the development of CIPN. [34,35] Thus, we recommend designing studies on CIPN that take these risk factors into account.CIPN leads to increased care needs in patients and a decrease in quality of life.[36] However, in our study, no difference was observed in the supportive care needs of patients with and without neuropathic pain. Sezgin (2021) reported a significant positive correlation between peripheral neuropathy and supportive care needs.[37] Contrary to our study, in Sezgin's study, patients were followed for three months after receiving neurotoxic chemotherapy to monitor the development of peripheral neuropathy; at the end of the third month, an increase in care needs correlated with the severity of peripheral neuropathy. In our study, only neuropathic pain and sensory evaluation were performed once among the symptoms of peripheral neuropathy. Neuropathic pain is influenced by treatment protocol, concurrent other health problems, and age,[38] and may be detected at different time intervals during chemotherapy, after the completion of the cycle, until the next cycle. Supportive care needs have been reported to vary with factors such as gender,[39,40] educational level,[41-43] economic status,[44,45] presence of chronic disease,[20] cancer type,[46,47] cancer stage,[48] treatment type, and treatment process. [48,49] In our study, all patients had breast cancer and received neurotoxic chemotherapy. Moreover, factors affecting supportive care needs, as mentioned in the literature, were normally distributed between the case and control groups, and the presence of neuropathic pain did not impact the supportive care needs. Hence, we propose that the relationship between neuropathic pain and supportive care needs be evaluated through large population studies with a follow-up period.
There are no studies in the literature that examine the effect of neuropathic pain on coping attitudes. Studies indicate that patients" attitudes towards coping with cancer are related to how they perceive the disease[50] and their level of anxiety.[51] In one study examining the general coping attitudes of cancer patients, coping attitudes and related factors were evaluated in poor women with breast cancer; age and income status were found to affect patients" coping attitudes in the areas of denial, acceptance, religion, self-blame, and planning. It has been reported that self-blame, planning, and acceptance decrease with increasing age.[12] In support of this study, Erbay et al.[52] reported that women's acceptance coping attitudes decreased with increasing age. In Lotfi's study,[12] there was significance in the sub-dimensions of religion and substance use with educational level and in the sub-dimensions of substance use, financial support, and self-blame with marital status. This result was interpreted as the fact that women with a low education level were more attached to religious elements was effective on the acceptance process.[12] Similarly, in our study, the educational level of the individuals was found to be low, and the most commonly used coping method was religious coping. In the study of Erbay et al.,[52] it was concluded that there was an increase in rejection coping attitude as the educational level increased. In another study conducted with Chinese women, it was reported that women from rural areas, who were widowed, had a low level of education, were young, and received chemotherapy, had lower coping skills.[53] In another study conducted in Iran on coping attitudes, 62 breast cancer patients were examined, and religion, acceptance, distraction, planning, active coping, positive reinterpretation, and rejection were listed as the most commonly used coping attitudes.[54] When coping attitudes are evaluated in general, it is seen that our study is similar to the literature. However, in our study, it was determined that there was no change in the coping attitudes of the patients according to the presence of neuropathic pain. This is thought to be related to the similarities in age and education between the case and control groups and the higher average age. It is thought that older patients have higher coping skills related to having reached a certain point in their life processes and having fulfilled certain goals and wishes. In fact, Akkanat Karagil (2023) emphasized in his study that the coping skills of cancer patients over the age of 30 were even better than those of cancer patients aged 18-30.[55] However, two studies in the literature emphasize the opposite findings.[56,57] Pennant et al.[57] found that the coping levels of cancer patients aged 18-30 years were higher, while Dempster et al.[56] reported that there was no significant difference in coping attitudes of cancer patients according to advanced age.
Conclusion
In the study, there was a significant difference between the groups according to the chemotherapy protocol. Patients" supportive care needs and coping attitudes did not change according to the presence of neuropathic pain. It was found that the care needs of the two groups were high; they needed more care support in the areas of health system and information, daily life, psychological needs, patient care support, and sexuality was the area where they needed the least care support. Additionally, it was determined that patients mostly used religion, positive reinterpretation, social support, and emotional support as coping methods; substance use among coping methods was at the lowest level.In this direction, it is recommended that followup studies be conducted on patients" care needs and coping attitudes of patients with cancer within the scope of the mechanism of action and risk factors of neuropathic pain in patients diagnosed with cancer; the studies should be planned by considering the factors affecting neuropathic pain, care needs, and coping attitudes. Furthermore, it is recommended that tools to assess neuropathic pain should be routinely used in clinical practice, and individualized holistic care should be provided by considering the supportive care needs and coping attitudes of patients.
Ethics Committee Approval: The study was approved by the İstanbul Gedik University Ethics Committee (no: 2022/3, date: 28/02/2022).
Authorship contributions: Concept -A.Ö., T.E.; Design - A.Ö., T.E.; Supervision - A.Ö.; Funding - T.E.; Data collection and/or processing - T.E.; Data analysis and/or interpretation - A.Ö., T.E.; Literature search - A.Ö., T.E.; Writing - A.Ö., T.E.; Critical review - A.Ö.
Conflict of Interest: All authors declared no conflict of interest. Use of AI for Writing Assistance: Not declared.
Financial Support: None declared.
Peer-review: Externally peer-reviewed.